New drug CPTX2309 enters first human safety trials for arthritis and lupus
Disease control
Recruiting now
This early-stage study tests a new drug, CPTX2309, to see if it is safe and tolerable. It involves 64 healthy adults and people with moderate to severe rheumatoid arthritis or lupus. Researchers will monitor side effects, lab results, and immune responses to determine the drug's …
Phase: PHASE1 • Sponsor: Capstan Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC